Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Surface oncology

EISAI

Eisai’s Lenvima gets FDA priority review for kidney cancer

The oncology treatment could now be approved in the US before the summer

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

Sanofi reception

Sanofi and Novartis snap up immuno-oncology candidates

Separate licensing deals see the firms look to catch up with the category's leaders

- PMLiVE

Nucala price far too high for US market, says ICER

Concludes GlaxoSmithKline's new severe asthma therapy is not value for money

- PMLiVE

Amgen buys back product rights from GSK

Prolia, Xgeva and Vectibix brought back in-house

- PMLiVE

Mixed news for gene therapies at ASH conference

GSK unveils successful trial, but there was disappointing news for Bluebird

- PMLiVE

GSK earns expanded approval for Volibris in Europe

Additional indication given to pulmonary arterial hypertension drug

- PMLiVE

GSK and AZ drugs impress in lupus trials

Raises hope for better treatment for debilitating disease

- PMLiVE

Allergan/Pfizer takeover talks confirmed

Talks still in early stage with no certainty of deal

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

- PMLiVE

GSK’s Breo fails to show survival benefit in COPD

Comes as GSK sees continued slump in sales

- PMLiVE

Gilead and GSK pulmonary hypertension drugs work in tandem

Letairis and Adcirca combined shows clear therapeutic benefit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links